The market doesn't appear to be overly excited about it ?
Perhaps due to the ambiguity of the announcement - no specific product mentioned and no upfront payment ?
Initial project is for the development of DEP® conjugates for an anti-infective drug, with an ability to add additional programs in other therapeutic areas.
Does anybody else think this is perhaps 'treading' on AstraZeneca's toes ? Or at the very least signing away AstraZeneca's rights in China / Asia for conjugates given our AZD0466 (DEP® Bcl2/xL conjugate) deal ? @Ima Scientist - thoughts ?
Agree @gaucau ... not overly excited about the "China" aspect .... especially given their reputation regarding accusations of patent copying / stealing - just sayin' ... have we done a deal with the devil ?
The market doesn't appear to be overly excited about it ? :(...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |